Business Wire

TX-MARY-KAY

12.1.2023 22:22:41 CET | Business Wire | Press release

Share
Mary Kay Inc. Company-Sponsored Foundations Give Millions Supporting Women's Causes Around the World

Throughout 2022, iconic beauty brand Mary Kay—along with its company-sponsored foundations—gave more than 3 million dollars to support women’s causes around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230112005756/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Female entrepreneurs in Chuxiong, Yunnan Province increased their income and helped preserve the Yunnan Embroidery cultural industry thanks to Mary Kay Women’s Entrepreneurship Program. (Photo: Mary Kay Inc.)

When Mary Kay Ash, legendary businesswoman and philanthropist, opened her business in 1963, she dreamed of empowering women internationally through entrepreneurship, innovation, hard work, and giving back. Nearly 60 years later, Mary Kay employees, Independent Beauty Consultants, and members of the global community keep her dream alive through generous contributions to four company-sponsored foundations delivering impactful support to women and their families in need.

The full foundation reports can be viewed here. Here’s what they were up to in 2022:

Cancers Affecting Women

  • In the U.S., the Mary Kay Ash Foundation (MKAF) funded 37 cancer researchers conducting groundbreaking research against cancers affecting women.
  • 43% of MKAF cancer research projects are led by women; 100% of clinical trials are women-led.
  • MKAF funded nearly $1.7 million in grants for cancers affecting women.

Gender-based Violence

  • MKAF funded nearly $1.4 million in grants supporting services for women survivors of domestic violence.
  • MKAF supported 4 local domestic violence shelters in North Texas providing women seeking help with vital resources and safety.
  • In collaboration with Mary Kay, MKAF supported global partners committed to end violence against women and girls, including CARE and UN Trust Fund. Together, MKAF partners completed over 550 projects around the world.
  • Instituto Mary Kay and Mary Kay Brazil received the Silver Award for the Red Cross Campaign “Campanha Sinal Vermelho Contra a Violência Doméstica” at ABEVD Associação Brasileira das Empresas de Venda Direta (Brazil DSA) Anual Congress.
  • In Canada, the Mary Kay Ash Charitable Foundation awarded $10,000 each to 16 domestic violence shelters across Canada, totaling $160,000.

Women and Their Families

Mary Kay China and its company-sponsored programs and fund have provided support through the following efforts:

  • Mary Kay Women’s Entrepreneurship Program
    • In cooperation with China Women’s Development Foundation, interest-free revolving loans were provided to four women entrepreneur initiatives in the provinces of Heilongjiang, Ningxia, and Jilin. The initiatives directly benefited 133 women by increasing their annual per capita income by RMB 20,000 yuan.

  • Young Women’s Future Fund
    • In cooperation with Adream Foundation, the Young Women’s Future Fund remaining balance will be used to build four Mary Kay Dream Classrooms in Jiangxi to enhance girls’ literacy education.

  • Mary Kay China Charity Program
    • Since March 2022, the Mary Kay China Charity Program has allocated 1,049,800 yuan to provide protective materials and living supplies to 73 communities in 15 cities as a result of the COVID-19 epidemic.
    • Thanks to the joint efforts of Mary Kay China and its Beauty Consultants, the "Smile 1000" project raised funds for 112 cleft-lip repair surgeries in 2022. To date, Mary Kay China has raised funds for 991 surgeries and is on track to achieve the goal of 1,000 smiles in 2023.
    • By May, 1,391 Beauty Consultant volunteers had delivered 331 beauty lessons to 9,147 women.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005756/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release

NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye